Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Introduction: Flash glucose monitoring (FGM) is a factory-calibrated sensor-based technology for the measurement of interstitial glucose. We performed a systematic review and meta-analysis to assess its efficacy and safety in patients with type 1 and type 2 diabetes. Research design and methods: PubMed, CENTRAL, Scopus and Web of Science were searched in July 2019. Twelve studies with a follow-up longer than 8 weeks, evaluating 2173 patients on prandial insulin, multiple daily insulin injections or continuous subcutaneous insulin infusion were included. The following data were extracted: HbA1c, time in range, time above 180 mg/dL, time below 70 mg/dL, frequency of hypoglycemic events, number of self-monitoring of blood glucose (SMBG) measurements, total daily insulin dose, patient-reported outcomes, adverse events, and discontinuation rate. A comparison with SMBG was conducted. Results: FGM use was associated with a reduction in HbA1c (−0.26% (−3 mmol/mol); p=0.002) from baseline to the last available follow-up, which correlated with HbA1c levels at baseline (−0.4% (−4 mmol/mol) for each 1.0% (11 mmol/mol) of HbA1c above 7.2% (55 mmol/mol)). Also, a decrease in time below 70 mg/dL was found (−0.60 hours/day; p=0.04). Favorable findings in patient-reported outcomes and no device-related serious adverse events were reported. When compared with SMBG, FGM was characterized by no statistically different change in HbA1c (p=0.09), with lower number of SMBG measurements per day (−3.76 n/day; p<0.001) and risk of discontinuation (relative risk=0.42; p=0.001). A limited number of studies, with a heterogeneous design and usually with a short-term follow-up and without specific training, were found. Conclusions: The present review provides evidence for the use of FGM as an effective strategy for the management of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A systematic review of RCTs in adults with type 1 or type 2 diabetes suggested that is-CGM may reduce HbA 1c in those with type 1 diabetes or insulin-treated type 2 diabetes (166), while another systematic review of studies (primarily in type 1 diabetes) with randomized or cohort designs suggested a small (0.26%) but statistically significant reduction in HbA 1c (167).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [167]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · BMJ · doi:10.1136/bmj.b2700 · Cited by 17,648
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Choosing effect measures and computing estimates of effect
Higgins, J. P., Li, T., & Deeks, J. J. (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch6 · Cited by 977 · cited 1×
“46 In the absence of this information in several studies and to include the largest number of studies, we estimated the data using an unpaired statistic, as stated.”
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893 · cited 1×
“For example, concerning the time above 180 mg/dL in patients with type 1 diabetes, FGM showed discordant findings in ref 7 and 16; however, the HbA1c at baseline in these studies was also significantly different (6.8±0.5% vs 7.9±1.0%, respectively; p<0.01).”
Influential6. Glycemic Targets: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s006 · Cited by 744
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541 · cited 1×
“25 26 Thus, we performed a meta-regression accordingly and found FGM to be associated with a reduction in HbA1c of −0.4% for 1.0% of HbA1c over 7.2% (−4 mmol/mol for each 11 mmol/ mol of HbA1c over 55 mmol/mol) (online supplementary figure S1).”
InfluentialYeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Study quality assessment tools
Graves, N., Wloch, C., Wilson, J. A., Barnett, A. G., Sutton, A. J., Cooper, N. J., Merollini, K. M. D., McCreanor, V., Cheng, Q., Burn, E., et al. (2016) · Cited by 440
7. Diabetes Technology: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s007 · Cited by 250
Dunn, T. C., Xu, Y., Hayter, G., & Ajjan, R. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.015 · Cited by 239
DeFronzo, R. A., Stonehouse, A. H., Han, J., & Wintle, M. E. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.02941.x · Cited by 213 · cited 1×
“25 26 Thus, we performed a meta-regression accordingly and found FGM to be associated with a reduction in HbA1c of −0.4% for 1.0% of HbA1c over 7.2% (−4 mmol/mol for each 11 mmol/ mol of HbA1c over 55 mmol/mol) (online supplementary figure S1).”
InfluentialYaron, M., Roitman, E., Aharon-Hananel, G., Landau, Z., Ganz, T., Yanuv, I., Rozenberg, A., Karp, M., Ish-Shalom, M., Singer, J., et al. (2019) · Diabetes Care · doi:10.2337/dc18-0166 · Cited by 211 · cited 11×
“No difference was found for change in time in range, time above 180 mg/dL, frequency of hypoglycemic events, and total daily insulin dose from baseline to the last available follow-up on FGM, as well as Emerging Technologies, Pharmacology and Therapeutics for differences in change in HbA1c or total daily insulin dose…”
InfluentialFokkert, M. J., van Dijk, P. R., Edens, M. A., Abbes, S., de Jong, D., Slingerland, R. J., & Bilo, H. J. G. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000320 · Cited by 209 · cited 1×
“37 38 Thus, while both FGM and RT-CGM can be regarded as effective options for CGM, some patient’s characteristics (eg, hypoglycemia unawareness) and the glycemic goals may lead to consider one over the other device.”
Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring
Edelman, S. V., Argento, N. B., Pettus, J., & Hirsch, I. B. (2018) · Diabetes Care · doi:10.2337/dc18-1150 · Cited by 199 · cited 1×
“39 In October 2019, a meta-analysis was published on the impact of FGM in patients with type 1 and type 2 diabetes.”
Pickup, J. C., Ford Holloway, M., & Samsi, K. (2015) · Diabetes Care · doi:10.2337/dc14-1855 · Cited by 189 · cited 1×
“35 36 5 Moreover, a negative bias at low glucose concentrations has been reported with FGM, possibly resulting in the patient inadvertently adapting to higher ‘true’ glucose concentrations and thus higher HbA1c.”
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0255-6 · Cited by 188
Evans, M., Welsh, Z., Ells, S., & Seibold, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00720-0 · Cited by 185 · cited 2×
“40 Limitations of the present paper should be discussed.”
Arditi, C., Rège-Walther, M., Wyatt, J. C., Durieux, P., & Burnand, B. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001175.pub3 · Cited by 175
Lawton, J., Blackburn, M., Allen, J., Campbell, F., Elleri, D., Leelarathna, L., Rankin, D., Tauschmann, M., Thabit, H., & Hovorka, R. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0239-1 · Cited by 174 · cited 1×
“35 36 5 Moreover, a negative bias at low glucose concentrations has been reported with FGM, possibly resulting in the patient inadvertently adapting to higher ‘true’ glucose concentrations and thus higher HbA1c.”
Ólafsdóttir, A. F., Attvall, S., Sandgren, U., Dahlqvist, S., Pivodic, A., Skrtic, S., Theodorsson, E., & Lind, M. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0392 · Cited by 173 · cited 1×
“29 It is worth noting that the definition of hypoglycemia differed among the included studies.”
Including non‐randomized studies on intervention effects
Reeves, B. C., Deeks, J. J., Higgins, J. P., Shea, B., Tugwell, P., Wells, G. A., & on behalf of the Cochrane Non‐Randomized Studies of Interventions Methods Group (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch24 · Cited by 153 · cited 2×
“42 Also, non-randomized studies should not be combined with randomized studies in a meta-analysis given the very different design features.”
Hermanns, N., Ehrmann, D., Schipfer, M., Kröger, J., Haak, T., & Kulzer, B. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.03.003 · Cited by 112
Adherence of self-monitoring of blood glucose in persons with type 1 diabetes in Sweden
Moström, P., Ahlén, E., Imberg, H., Hansson, P.-O., & Lind, M. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000342 · Cited by 110 · cited 1×
“2 30 In the included studies, the mean number of sensor scan per day ranged from 7.5±4.2 to 17.8±9.9.”
InfluentialPark, C., & Le, Q. A. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0177 · Cited by 104 · cited 1×
“40 43–45 Concerning the inclusion of patients with different types of diabetes, according to current guidelines, FGM can be considered in patients with type 1 diabetes or type 2 diabetes to lower HbA1c levels and/or reduce hypo-glycemia.”
Al Hayek, A. A., Robert, A. A., & Al Dawish, M. A. (2017) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551417746957 · Cited by 103
Campbell, F. M., Murphy, N. P., Stewart, C., Biester, T., & Kordonouri, O. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12735 · Cited by 102 · cited 1×
“For example, concerning the time above 180 mg/dL in patients with type 1 diabetes, FGM showed discordant findings in ref 7 and 16; however, the HbA1c at baseline in these studies was also significantly different (6.8±0.5% vs 7.9±1.0%, respectively; p<0.01).”
InfluentialArditi, C., Rège-Walther, M., Durieux, P., & Burnand, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001175.pub4 · Cited by 96
Treatment of Functional Hypogonadism Besides Pharmacological Substitution
Corona, G., Rastrelli, G., Morelli, A., Sarchielli, E., Cipriani, S., Vignozzi, L., & Maggi, M. (2020) · The World Journal of Men's Health · doi:10.5534/wjmh.190061 · Cited by 87
Ida, S., Kaneko, R., & Murata, K. (2019) · Journal of Diabetes Research · doi:10.1155/2019/4684815 · Cited by 86
Paris, I., Henry, C., Pirard, F., Gérard, A., & Colin, I. M. (2018) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.23 · Cited by 84 · cited 1×
“14 15 21 Therefore, the result of the present meta-analysis, showing no change in the frequency of hypoglycemic events with FGM, could potentially be biased.”
Opioid antagonists with minimal sedation for opioid withdrawal
Gowing, L., Ali, R., & White, J. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002021.pub4 · Cited by 79
Moser, O., Eckstein, M. L., McCarthy, O., Deere, R., Pitt, J., Williams, D. M., Hayes, J., Sourij, H., Bain, S. C., & Bracken, R. M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13835 · Cited by 76
Bruttomesso, D., Laviola, L., Avogaro, A., Bonora, E., Del Prato, S., Frontoni, S., Orsi, E., Rabbone, I., Sesti, G., & Purrello, F. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.01.018 · Cited by 72
Self-citationFlash Glucose Monitoring: A Review of the Literature with a Special Focus on Type 1 Diabetes
Mancini, G., Berioli, M. G., Santi, E., Rogari, F., Toni, G., Tascini, G., Crispoldi, R., Ceccarini, G., & Esposito, S. (2018) · Nutrients · doi:10.3390/nu10080992 · Cited by 70 · cited 1×
“35 36 5 Moreover, a negative bias at low glucose concentrations has been reported with FGM, possibly resulting in the patient inadvertently adapting to higher ‘true’ glucose concentrations and thus higher HbA1c.”
Messaaoui, A., Tenoutasse, S., & Crenier, L. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0339 · Cited by 51
Landau, Z., Abiri, S., Gruber, N., Levy-Shraga, Y., Brener, A., Lebenthal, Y., Barash, G., Pinhas-Hamiel, O., & Rachmiel, M. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1218-8 · Cited by 48
Al Hayek, A. A., Robert, A. A., & Al Dawish, M. A. (2019) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/1179551419861102 · Cited by 44 · cited 1×
“2 However, in some studies it was described as any glucose level ≤ 70 mg/dL 14 15 , while in other studies it was represented by any FGM-derived glycemic measures 70 mg/dL, confirmed by a second reading in the following 15 min.”
Ye, J., Huang, W., Huang, G., Qiu, Y., Peng, W., Lan, N., Xie, X., & Liu, B. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1734673 · Cited by 42
Flash Glucose Monitoring: The Future Is Here
Garg, S. K., & Akturk, H. K. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0098 · Cited by 31
Jangam, S. R., Dunn, T. C., Xu, Y., Hayter, G., & Ajjan, R. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000611 · Cited by 30 · cited 1×
“41 Also, the reason for the discrepancy between the number of posters, letters and commentaries versus published articles is unclear.”
Moreno-Fernández, J., Pazos-Couselo, M., González‐Rodríguez, M., Rozas, P., Delgado‐Rodríguez, M., Aguirre, M., & López, J. M. G. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.04.003 · Cited by 28 · cited 1×
“19 20 This implies that patients or their caregivers feel confident in measuring glucose any time they believe this to be necessary, anyway more often than with SMBG.”
FreeStyle Libre: contact irritation versus contact allergy
Aerts, O., Herman, A., Bruze, M., Goossens, A., & Mowitz, M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32142-6 · Cited by 24 · cited 1×
“31 Patients should be informed about these issues, and sensor application sites regularly checked.”
Kramer, G., Michalak, L., Müller, U., Kloos, C., Werner, C., & Kuniß, N. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0875-3988 · Cited by 23 · cited 12×
“No difference was found for change in time in range, time above 180 mg/dL, frequency of hypoglycemic events, and total daily insulin dose from baseline to the last available follow-up on FGM, as well as Emerging Technologies, Pharmacology and Therapeutics for differences in change in HbA1c or total daily insulin dose…”
InfluentialPleus, S., Heinemann, L., & Freckmann, G. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817753629 · Cited by 18 · cited 1×
“37 38 Thus, while both FGM and RT-CGM can be regarded as effective options for CGM, some patient’s characteristics (eg, hypoglycemia unawareness) and the glycemic goals may lead to consider one over the other device.”
Cao, B., Wang, R., Gong, C., Wu, D., Su, C., Chen, J., Yi, Y., Liu, M., Liang, X., & Li, W. (2019) · Journal of Diabetes Research · doi:10.1155/2019/4845729 · Cited by 14
Gernay, M.-M., Philips, J., Radermecker, R. P., & Paquot, N. (2018) · RMLG. Revue médicale de Liège · Cited by 4
Gernay, M., Philips, J. C., Radermecker, R. P., et al. (2018) · PubMed · Cited by 3
Cited by
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
7. Diabetes Technology: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s007 · Cited by 202
“26%) in people with type 1 and type 2 diabetes, but there was no difference in time in range or hypoglycemic episodes (83).”
BackgroundContinuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis
Jancev, M., Vissers, T. A. C. M., Visseren, F. L. J., van Bon, A. C., Serné, E. H., DeVries, J. H., de Valk, H. W., & van Sloten, T. T. (2024) · Diabetologia · doi:10.1007/s00125-024-06107-6 · Cited by 191
Sacks, D. B., Arnold, M. A., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad080 · Cited by 206
Seidu, S., Kunutsor, S. K., Ajjan, R. A., & Choudhary, P. (2024) · Diabetes Care · doi:10.2337/dc23-1520 · Cited by 124
Metadata
- Authors
- Castellana, M., Parisi, C., Di Molfetta, S., Di Gioia, L., Natalicchio, A., Perrini, S., Cignarelli, A., Laviola, L., & Giorgino, F.
- Affiliations
- University of Bari Aldo Moro (IT)
- Department of Emergency and Organ Transplantation, University of Bari, Bari, Puglia, Italy
- Corresponding author
- Giorgino, Francesco
- ORCID
- Venue
- BMJ Open Diabetes Research & Care
- Publisher
- BMJ
- Published
- 2020-06
- Volume
- 8
- Issue
- 1
- Pages
- e001092
- ISSN
- 2052-4897 (ISSN-L)
- PMC
- PMC7265013
- OpenAlex
- W3031454518
- Semantic Scholar
- 9811ea1d23ef17f58a9442d9c1d366f5ea858327
- Cited by
- 84
- References
- 53
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 14 · 2023: 19 · 2022: 22 · 2021: 13 · 2020: 2
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMJ Open Diabetes Research & Care (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- flash glucose monitoring, type 1 diabetes, type 2 diabetes, glycemic control, HbA1c, hypoglycemia, time in range, self-monitoring of blood glucose, continuous glucose monitoring, insulin therapy, device safety, patient-reported outcomes
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Glucose, Humans, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.